Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$47.68 USD
-2.22 (-4.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.68 USD
-2.22 (-4.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
by Zacks Equity Research
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Why Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
by Zacks Equity Research
The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Relay Therapeutics, Inc. (RLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?
by Zacks Equity Research
Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device
by Zacks Equity Research
Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.
Why Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy
by Zacks Equity Research
Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
by Zacks Equity Research
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
by Zacks Equity Research
InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
by Zacks Equity Research
Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review
by Zacks Equity Research
Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension
by Zacks Equity Research
The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.
Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints
by Zacks Equity Research
Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.